Guidance
Reporting adverse incidents: neurostimulators
For manufacturers reporting adverse incidents with neurostimulators under the vigilance system.
Documents
Details
Guidance for manufacturers on reporting adverse incidents involving stimulators under the vigilance system.
To be read in conjunction with the guidelines on post-market surveillance.
Updates to this page
Published 1 June 2013
Last updated 15 January 2025
show all updates
-
Updated to reflect the laying of 皇冠体育app Medical Devices (Post-market Surveillance requirements) (Amendment) Regulations 2024.
-
This page has been updated due to the end of the transition period.
-
First published.